Welcome to our dedicated page for Adlai Nortye Ltd. SEC filings (Ticker: ANL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adlai Nortye Ltd. (NASDAQ: ANL) SEC filings page on Stock Titan provides access to the company’s public reports as a foreign private issuer, including Form 20-F annual reports and Form 6-K current reports. Adlai Nortye prepares its consolidated financial statements in accordance with IFRS as issued by the International Accounting Standards Board and presents its results in U.S. dollars, giving investors a standardized view of its clinical-stage biotechnology operations.
In its Form 6-K filings, the company reports unaudited financial information such as statements of operations, financial position, cash flows and changes in shareholders’ equity. These filings show that Adlai Nortye is a clinical-stage company with no reported revenue in the periods presented, and that its operating results are driven primarily by research and development and administrative expenses related to oncology drug development. They also disclose cash and restricted cash balances, interest-bearing bank borrowings, contract liabilities and accumulated deficits, helping readers assess liquidity and capital structure.
Beyond financial data, Adlai Nortye’s 6-Ks include narrative updates on its oncology pipeline, describing the status of programs such as Buparlisib (AN2025), AN4005, AN8025, AN9025, AN4035 and AN0025, as well as expectations for clinical milestones. Other filings detail governance matters, including adoption of the 2025 Share Incentive Plan, director resignations and appointments, committee composition and notices of shareholder meetings.
On Stock Titan, these filings are updated as they are posted to EDGAR, and AI-powered summaries can help explain key points in complex documents, from financial trends to pipeline disclosures and board changes. Users can review quarterly and semiannual financial updates, equity and incentive plan information, and other regulatory disclosures in one place when researching ANL stock and Adlai Nortye’s development trajectory.
Adlai Nortye Ltd. files Amendment No. 2 to its Form F-3 registration statement (File No. 333-294173) dated April 24, 2026 to furnish legal opinions as Exhibits 5.1 and 23.3 and to update Part II exhibit indexing and signatures. The prospectus in Part I remains unchanged.
Adlai Nortye Ltd. is registering a shelf of up to $600,000,000 of securities and registration for resale of up to 98,577,627 Class A ordinary shares (represented by 32,859,209 ADSs) by selling shareholders.
The prospectus states the company will not receive proceeds from sales by the selling shareholders; the offering may include ADSs, ordinary shares, debt securities, warrants, rights and units and may be sold on Nasdaq or in private transactions. The filing discloses recent private placements that raised approximately $140.0M in February 2026 and $150.0M in April 2026 and lists Nasdaq last sale price of $16.60 per ADS as of April 20, 2026.
Adlai Nortye Ltd. entered into a Securities Purchase Agreement for a private placement of its equity. The company agreed to sell up to 33,962,265 Ordinary Shares, equivalent to 11,320,755 ADSs, at a purchase price of $13.25 per ADS (about $4.4167 per Ordinary Share). The deal is conducted under a private offering exemption and includes customary closing conditions, legal opinions, lock-up agreements from executives and key shareholders, and detailed investor representations. Purchasers receive registration rights requiring Adlai Nortye to file and seek effectiveness of a resale registration statement within defined deadlines so investors can later resell their shares in the public market.
Adlai Nortye Ltd., a Cayman Islands holding company with operations in the U.S. and mainland China, files its annual Form 20-F, highlighting its ADS listing on Nasdaq and a dual-class share structure totaling 120,000,803 ordinary shares as of December 31, 2025.
The report explains heavy reliance on subsidiaries for cash, detailed intercompany loans and capital contributions, and the impact of PRC foreign exchange and tax rules on upstreaming funds. It also stresses regulatory risks from the HFCAA, evolving Chinese oversight of overseas listings, and extensive intellectual property and clinical-development uncertainties for its drug pipeline.
Adlai Nortye Ltd. announced several leadership changes effective April 1, 2026. Archie Tse, M.D., Ph.D., was appointed President while continuing as Head of Research and Development, a role he has held since March 2024. His background includes senior R&D positions at multinational pharmaceutical companies.
The Board also appointed Dr. Ye as Chief Financial Officer, in addition to his responsibilities for business development and global commercialization strategy, after serving as interim CFO since January 2025. He brings experience in business development and commercial leadership across the Asia-Pacific region.
Current President Dr. Kaiyang Tang retired from the president role on April 1, 2026 and will remain as a Corporate Strategy Professor to support a smooth transition. The company states his retirement does not affect operations in finance, investor relations, or public relations, and that he has no disputes or disagreements with the company.
Adlai Nortye Ltd. filed a Form F-3 shelf registration to offer up to US$600,000,000 of Class A ordinary shares and to register for resale up to 64,615,386 Class A ordinary shares (represented by 21,538,462 ADSs), from time to time after the effective date. The prospectus states the selling shareholders’ sales will provide no proceeds to the company, and that ADSs trade on Nasdaq under the symbol ANL. The prospectus describes the securities, dual-class share structure, risk factors including HFCAA-related delisting risk, and that specific offering terms will be provided in prospectus supplements.
Adlai Nortye Ltd. reported that the first patient has been dosed in a global Phase 1 clinical trial of AN9025, its oral pan-RAS(ON) inhibitor for advanced or metastatic solid tumors with RAS mutations. This first-in-human, multicenter, open-label study will assess safety, tolerability, pharmacokinetics and early anti-tumor activity.
The trial is being run as a multi-regional clinical trial in collaboration with ASK Pharm, with Adlai Nortye holding rights to AN9025 outside mainland China, Hong Kong and Macao. AN9025 is part of the company’s broader oncology pipeline, which also includes next-generation cancer immunotherapies and additional RAS-targeting candidates.
Venrock-affiliated investment funds and two principals report a passive 6.1% ownership stake in Adlai Nortye Ltd. They beneficially own 9,638,193 ordinary shares, held through American Depositary Shares, each representing three ordinary shares.
The stake is spread across three Venrock Healthcare Capital vehicles, with governance handled by Delaware management entities linked to Nimish Shah and Bong Y. Koh. The ownership percentage is calculated against 93,710,803 ordinary shares outstanding as of June 30, 2025, plus 64,615,386 ordinary shares issued in a February 4, 2026 private placement. The group certifies the shares are not held to change or influence control of Adlai Nortye.
Adlai Nortye Ltd. saw a major institutional holder file an amended ownership report showing it no longer owns any of the company’s American Depositary Shares. Unique Mark Ventures Limited and its parent Fine Process Limited each report beneficial ownership of 0.00 shares, or 0.00% of the class.
The filing explains that Unique Mark Ventures, wholly owned by Fine Process and ultimately linked to ICBC group entities, has disposed of all its shares and ceased to be a shareholder as of this amendment. All voting and dispositive power figures in the report are listed as zero.
Adlai Nortye Ltd. entered into securities purchase agreements for a private placement equity financing expected to raise approximately $140.0 million in gross proceeds, before fees and expenses. The company is selling 64,615,386 Class A ordinary shares, equivalent to 21,538,462 ADSs, at $2.1667 per ordinary share (or $6.50 per ADS).
The private placement, co-led by Cormorant Asset Management and Columbia Threadneedle Investments with several other institutional investors, is expected to close on February 4, 2026, subject to customary conditions. Around $55 million of shares will be purchased by entities controlled by Chairman and CEO Yang Lu. Adlai Nortye agreed to file a registration statement covering resale of the ADSs issued in the financing.